Evidence map›Paper›PMID 29769208›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018

Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.

Jeff K Davies, Lisa L Brennan, John R Wingard, Christopher R Cogle, Neena Kapoor, Ami J Shah, Bimalangshu R Dey, Thomas R Spitzer, Marcos de Lima, Laurence J Cooper and 4 more

Registry-linked trialOpen access · greenAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00376480 (Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00376480 phase1completednot on this map

Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2005 to 2018Enrolled19ConditionsLeukemia, Myelodysplastic SyndromesArmsanti-thymocyte globulin, peripheral blood lymphocyte therapy, fludarabine phosphate, methylprednisolone, thiotepa
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 2 countries.

Jeff K DaviesCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Lisa L BrennanDana-Farber Cancer Institute, Boston, Massachusetts.
John R WingardUniversity of Florida College of Medicine, Gainesville, Florida.ORCID 0000-0001-7478-5398
Christopher R CogleUniversity of Florida College of Medicine, Gainesville, Florida.
Neena KapoorChildren's Hospital Los Angeles, Los Angeles, California.
Ami J ShahDivision of Stem Cell Transplantation and Regenerative Medicine, Lucille Packard Children's Hospital, Stanford University School of Medicine, Stanford, California.
Bimalangshu R DeyBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
Thomas R SpitzerBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, Massachusetts.
Marcos de LimaBone Marrow Transplant, University Hospital Cleveland Medical Center, Cleveland, Ohio.
Laurence J CooperDivision of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Peter F ThallDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Richard E ChamplinDepartment of Stem Cell Transplant and Cellular Therapies, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lee M NadlerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Eva C GuinanRadiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. eva_guinan@dfci.harvard.edu.
The University of Texas MD Anderson Cancer Center · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USUniversity of Florida · USChildren's Hospital of Los Angeles · USHarvard University · USLucile Packard Children's Hospital · USQueen Mary University of London · GBUniversity Hospitals Cleveland Medical Center · US

Funding

Specific Control of donor Anti-host AlloreactiviyU19CA100265 · NCI · DANA-FARBER CANCER INST · PI REISNER, YAIR · 2006 to 2008
$10.3M
Ex Vivo Alloanergization to Improve Immunity After Haploidentical TransplantR21CA137645 · NCI · DANA-FARBER CANCER INST · PI GUINAN, EVA C · 2009 to 2010
$745k
Medical Research Council G0902269NCI NIH HHS R21 CA137645NCI NIH HHS U19 CA100265
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationAdultAntigens, CD34CD4-Positive T-LymphocytesFemaleGraft vs Host DiseaseHumansImmunity, InnateLeukemiaLymphocytesLymphocyte TransfusionMaleMiddle AgedMyeloablative AgonistsMyelodysplastic SyndromesTissue DonorsAntigens, CD34Myeloablative Agonists

Identifiers

PMID29769208
PMCPMC6125184
OpenAlexW2803523989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.